Business
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
- Late-breaking poster presentation features LIVMARLI® data showing long-term maintenance of response in patients with PFIC - Four poster presentations
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Late-breaking poster presentation features LIVMARLI® data showing long-term maintenance of response in patients with PFIC\n\n\n- Four poster presentations highlight LIVMARLI PFIC data as well as a poster with proof-of-concept trial data from volixibat study in intrahepatic cholestasis of pregnancy\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.\n\n\nData were presented from the Phase 3 MARCH study and MARCH-ON extension evaluating the efficacy and safety of LIVMARLI in patients with progressive familial intrahepatic cholestasis (PFIC) as well as the Phase 2 OHANA study evaluating the efficacy and safety of volixibat in patients with intrahepatic cholestasis of pregnancy (ICP).\n\n\nMARCH was the largest and most genetically diverse trial of PFIC to date, enrolling patients with deficiencies of BSEP, FIC1, MDR3, TJP2, AND MYO5B, as well as those clinically diagnosed with PFIC but without a known genetic variant.\n\n\n“PFIC is a chronic, debilitating cholestatic liver disease characterized by elevated bile acids and pruritus so severe that patients can be listed for liver transplant even in the absence of disease progression. We are excited to share the long-term benefits observed across multiple measures including reductions in pruritus, serum bile acids, improved liver health and growth for patients with PFIC treated with maralixibat in multiple genetic types which have not previously been reported,” said Pam Vig, PhD, head of research and development at Mirum. “We are also pleased to share the findings from the OHANA study of volixibat in patients with ICP, showing a clear impact of volixibat on serum bile acids and pruritus in this cholestatic setting.”\n\n\nA summary of these data presented is featured below. Full presentations can be found within the Publications and Presentations section of Mirum’s website.\n\n\nLate-breaker Poster Presentation\n\n\nPoster 5048-C: Long-term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): 2-year data from the MARCH-ON study\n\n\nThe MARCH-ON extension study ...